Рет қаралды 2,669
Lee Schwartzberg, MD, FACP; Adam M. Brufsky, MD, PhD, FACP; Hope S. Rugo, MD; Francisco Esteva, MD, PhD; and Komal Jhaveri, MD, FACP, discuss the role of fulvestrant with a CDK4/6 inhibitor or alone in metastatic hormone receptor-positive breast cancer.